Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes .1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines
被引:102
作者:
Rondu, F
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Rondu, F
LeBihan, G
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
LeBihan, G
Wang, X
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Wang, X
Lamouri, A
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Lamouri, A
Touboul, E
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Touboul, E
Dive, G
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Dive, G
Bellahsene, T
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Bellahsene, T
Pfeiffer, B
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Pfeiffer, B
Renard, P
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Renard, P
GuardiolaLemaitre, B
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
GuardiolaLemaitre, B
Manechez, D
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Manechez, D
Penicaud, L
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Penicaud, L
Ktorza, A
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Ktorza, A
Godfroid, JJ
论文数: 0引用数: 0
h-index: 0
机构:UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
Godfroid, JJ
机构:
[1] UNIV PARIS 07,CNRS,URA 307,LAB PHARMACOCHIM MOL,F-75251 PARIS,FRANCE
[2] UNIV PARIS 07,CNRS,URA 307,LAB PHYSIOPATHOL NUTR,F-75251 PARIS,FRANCE
[3] ADIR,F-92415 COURBEVOIE,FRANCE
[4] INST RECH INT SERVIER,F-92415 COURBEVOIE,FRANCE
The physiopathology of non-insulin-dependent diabetes mellitus is associated with a dysfunction in the regulation of insulin secretion. The alpha(2)-adrenoceptors have been reported to be involved in this alteration, although at-antagonists containing an imidazoline ring may stimulate insulin secretion independently of alpha(2)-adrenoceptor blockage. Recently, a new ''imidazoline-binding site'' involved in the control of K+-ATP channels in the B cell has been proposed. In the course of searching for new antidiabetic agents, 1-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines, 1-benzyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl) and 1-benzyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)-4-benzylpiperazines have been designed and evaluated as potential adrenoceptor antagonists. Pharmacological evaluation was performed in vivo using glucose tolerance tests performed on a rat model of type II diabetes obtained by injection of a low dose (35 mg/kg) of streptozotocin (STZ). For some compounds, binding experiments were performed on alpha(2) adrenoceptors and I-1 and I-2 imidazoline-binding sites. The biological and physicochemical data have been combined with molecular modeling studies to establish structure-activity relationships. The most active compound was 1-(2',4'-dichlorobenzyl)-2 (4',5'-dihydro-1'H-imidazol-2'-yl)-4-methylpiperazine (7f); intraperitoneal administration (100 mu mol/kg) of 7f strongly improved glucose tolerance in STZ diabetic rats. This effect seemed at least partly mediated by a significant increase of insulin secretion. Other compounds of the same family (7b, 16f, 23b) have also shown potent activity. We found no correlation between in vivo antihyperglycemic properties and in vitro affinities for alpha(2)-adrenoceptors or I-1 and I-2 binding sites. These compounds can be considered as antihyperglycemic agents potentially useful for treatment of type II diabetes and are currently under complementary investigation.